XTRA:ACTChemicals
Is AlzChem Group (XTRA:ACT) Quietly Recasting Its Growth Story Around Creatine Nutrition Demand?
In December 2025, AlzChem Group AG approved a roughly €120 million investment program to build a more automated creatine production plant and related infrastructure, with phased commissioning scheduled from the second half of 2027 to capture additional demand in sports, food, and health.
The company links this capacity expansion to early triple-digit million euro annual sales potential from its Creapure® and Creavitalis® lines, underscoring how nutrition and wellness trends are reshaping its...